Selective inhibition of cGMP-inhibited and cGMP-noninhibited cyclic nucleotide phosphodiesterases and relaxation of rat aorta
- PMID: 1650216
- DOI: 10.1016/0006-2952(91)90317-x
Selective inhibition of cGMP-inhibited and cGMP-noninhibited cyclic nucleotide phosphodiesterases and relaxation of rat aorta
Abstract
In the supernatant (50,000 g, 1 hr) fraction from rat aortic smooth muscle homogenates, approximately 50% of total cAMPE PDE activity was inhibited by OPC 3911 (3 microM), while approximately 20% was inhibited by rolipram (30 microM). A cGMP-inhibited cyclic nucleotide phosphodiesterase (cGI-PDE) was further purified using DEAE chromatography followed by affinity chromatography on the N-(2-isothiocyanato)ethyl derivative of cilostamide conjugated to aminoethyl agarose (CIT-agarose). OPC 3911, CI-930, and milrinone, but not rolipram, were potent and selective inhibitors of this enzyme. The PDE-activity in the CIT-agarose flow through fraction (RI-PDE), however, was inhibited potently by rolipram, but not by cGMP, OPC 3911, CI-930 or milrinone. Functional studies showed that OPC 3911, CI-930, and milrinone were potent relaxants of contracted rat aorta. Rolipram had little relaxant effect. When OPC 3911 or milrinone was combined with rolipram more than additive effects on aortic relaxation and cAMP content were obtained. OPC 3911 combined with milrinone had only additive effects. These results demonstrate the presence of a cGI-PDE in rat aortic smooth muscle, and that inhibition of this isozyme may be of primary importance for the relaxant effects of OPC 3911, CI-930, and milrinone. A RI-PDE activity was also found, but it appeared to be less important for modulation of vascular tone unless the cGI-PDE was already inhibited. This may explain the synergistic relaxant effects observed when both PDE-isozymes were inhibited.
Similar articles
-
Endothelium-dependent and independent relaxation of the rat aorta by cyclic nucleotide phosphodiesterase inhibitors.Br J Pharmacol. 1991 Oct;104(2):495-503. doi: 10.1111/j.1476-5381.1991.tb12457.x. Br J Pharmacol. 1991. PMID: 1665741 Free PMC article.
-
Comparison of cyclic nucleotide phosphodiesterase isoenzymes in rat and rabbit ventricular myocardium: positive inotropic and phosphodiesterase inhibitory effects of Org 30029, milrinone and rolipram.Naunyn Schmiedebergs Arch Pharmacol. 1990 Dec;342(6):698-705. doi: 10.1007/BF00175715. Naunyn Schmiedebergs Arch Pharmacol. 1990. PMID: 1710786
-
Cellular distribution of phosphodiesterase isoforms in rat cardiac tissue.Circ Res. 1991 Apr;68(4):1070-9. doi: 10.1161/01.res.68.4.1070. Circ Res. 1991. PMID: 1849058
-
Biochemical aspects of inhibition of cardiovascular low (Km) cyclic adenosine monophosphate phosphodiesterase.Am J Cardiol. 1989 Jan 3;63(2):2A-8A. doi: 10.1016/0002-9149(89)90384-6. Am J Cardiol. 1989. PMID: 2535910 Review.
-
Inhibitors of cyclic nucleotide phosphodiesterases as therapeutic agents.Biochem Soc Trans. 1992 May;20(2):460-4. doi: 10.1042/bst0200460. Biochem Soc Trans. 1992. PMID: 1327922 Review. No abstract available.
Cited by
-
Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype.J Clin Invest. 1997 Nov 15;100(10):2611-21. doi: 10.1172/JCI119805. J Clin Invest. 1997. PMID: 9366577 Free PMC article.
-
Cytochemical distribution of cyclic AMP-dependent 3',5'-nucleotide phosphodiesterase in the rat myocardium.Histochem J. 1996 Mar;28(3):165-72. doi: 10.1007/BF02331440. Histochem J. 1996. PMID: 8735283
-
Effects of two vasodilatory phosphodiesterase inhibitors on bradykinin-induced permeability increase in the hamster cheek pouch.Agents Actions. 1993 May;39(1-2):35-41. doi: 10.1007/BF01975712. Agents Actions. 1993. PMID: 8285138
-
Stereospecificity of rolipram actions on eosinophil cyclic AMP-specific phosphodiesterase.Biochem J. 1993 Apr 15;291 ( Pt 2)(Pt 2):389-95. doi: 10.1042/bj2910389. Biochem J. 1993. PMID: 8387267 Free PMC article.
-
Role of phosphodiesterases III and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway.Br J Pharmacol. 1994 Oct;113(2):445-50. doi: 10.1111/j.1476-5381.1994.tb17009.x. Br J Pharmacol. 1994. PMID: 7834194 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources